Annual report highlights progress in cancer research
The American Association for Cancer Research has released its annual Cancer Progress Report, highlighting significant progress in cancer research. The report underscores the approval of 11 new anticancer therapeutics by the U.S. Food and Drug Administration between July 2025 and June 2026, including a molecularly targeted therapy for a rare brain tumor, the first immune checkpoint inhibitor for ovarian cancer, and the first approval of a proteolysis-targeting chimera for breast cancer patients.
Additionally, the FDA approved new uses for five previously approved anticancer therapies, a wearable noninvasive device for pancreatic cancer treatment, and various AI-based tools to enhance early detection and diagnosis of cancers. The report also explores emerging areas such as weight-loss interventions, AI in cancer research and drug development, and preventive and therapeutic vaccines.
Keith Flaherty, M.D., chair of the AACR Cancer Progress Report 2026 Steering Committee, emphasized the rapid progress in cancer research and the need for continued investment in medical research, collaboration, and support for the next generation of cancer scientists.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
